PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

Abstract Background The poly ADP ribose polymerase (PARP) inhibitor olaparib has been approved for treating prostate cancer (PCa) with BRCA mutations, and veliparib, another PARP inhibitor, is being tested in clinical trials. However, veliparib only showed a moderate anticancer effect, and combinati...

Full description

Bibliographic Details
Main Authors: Linglong Yin, Youhong Liu, Yuchong Peng, Yongbo Peng, Xiaohui Yu, Yingxue Gao, Bowen Yuan, Qianling Zhu, Tuoyu Cao, Leye He, Zhicheng Gong, Lunquan Sun, Xuegong Fan, Xiong Li
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
PARP inhibitor
HDAC inhibitor
DNA damage
DNA repair
Synergistic effect
Online Access:http://link.springer.com/article/10.1186/s13046-018-0810-7

Internet

http://link.springer.com/article/10.1186/s13046-018-0810-7

Similar Items